Achillion upgraded to Outperform from Market Perform at Wells Fargo Wells Fargo upgraded Achillion to Outperform citing the potential for multiple near-term catalysts around the company's hepatitis C portfolio. Wells raised its price target range for shares to $11-$13 from $7-$8. Achillion was also upgraded this morning at Piper Jaffray.
News For ACHN From The Last 14 Days
Check below for free stories on ACHN the last two weeks.